Table 1.
Baseline Characteristics a of Nondialysis Chronic Kidney Disease Patients Prescribed Oral Nutritional Supplements (N = 3957).
| Age (years) | 76.5 (66.5, 83.6) |
| Female (%) | 1838 (46.5%) |
| Comorbidities (%) | |
| Diabetes | 2074 (52.4%) |
| Hypertension | 3141 (79.4%) |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 23 (16, 31) |
| Cause of CKD | |
| Hypertension | 683 (17.3%) |
| Diabetes | 577 (14.6%) |
| Polycystic | 59 (1.5%) |
| Congenital | 18 (0.5%) |
| Glomerulonephritis/Autoimmune | 304 (7.7%) |
| Other | 1782 (45.0%) |
| Unknown | 815 (20.6%) |
| Urine albumin-to-creatinine ratio (mg/mmol) | 28.4 (5.1, 141.8) |
| Body mass index (kg/m2) | 24.6 (21.8, 28.3) |
| Serum albumin (g/L) | 39 (35, 42) |
| Serum phosphate (mmol/L) | 1.3 (1.1, 1.5) |
| Serum bicarbonate (mmol/L) | 24 (22, 27) |
| Serum ferritin (µg/L) | 157 (77, 325) |
| Iron saturation (%) | 23 (17, 31) |
| Hemoglobin (g/L) | 108 (97, 120) |
| Parathyroid hormone (pmol/L) | 12.2 (7.3, 19.9) |
| Neutrophil-to-lymphocyte ratio | 3.3 (2.3, 5.2) |
Note. Results expressed as median (interquartile range) or number (percentage). CKD = chronic kidney disease.
a
Within 12 months prior to the first prescription of oral nutritional supplements.